Scandinavian Cardiovascular Journal · 2004 · 18 citations · 26 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical CardiologyPreventive CardiologyCardiac MedicationsCardiac PharmacotherapyCardiovascular DiseaseCardiovascular PhysiologyIschemic Heart DiseaseMyocardial ProtectionCardioprotective TherapyInfarct Size AssessmentLeft Ventricular PhysiologyLipid Peroxidation MarkersPost-myocardial Infarction PharmacotherapyPreconditioning
OBJECTIVES: The efficacy of ischemic preconditioning of the heart has remained controversial. We investigated whether chronic treatment with beta-blockers affects the ischemic preconditioning in the isolated rat heart model. DESIGN: Wistar rats were treated with propranolol (50 mg/kg/day, p.o.) (PRL), with nipradilol (10 mg/kg/day, p.o.) (NPL), or with vehicle, for 4 weeks. Isolated rat hearts were divided into global ischemia hearts (GI, PRL and NPL, each n=6) and ischemic preconditioned hearts (IP, PRL+IP and NPL+IP, each n=6). RESULTS: Significant differences in left ventricular pressure were observed between the PRL and PRL+IP, and between the NPL and NPL+IP groups. In the NPL group, significant amelioration and preservation of left ventricular peak pressure, coronary flow, reduction of infarct size, and NOx preservation were observed. Lipid peroxidation in the NPL group was significantly reduced before and after global ischemia compared to the GI group. CONCLUSIONS: The effect of ischemic preconditioning was abolished in the hearts of rats following oral treatment of propranolol or nipradilol. However, the administration of nipradilol protected the ischemic and reperfused myocardium, partly due to the prevention of lipid peroxide formation.
26
Preconditioning does not attenuate myocardial stunning.
Michel Ovize, Karin Przyklenk, S L Hale et al. · Circulation · 1992 · 191 citations · Full text